Key result
Doxorubicin cuts cardiomyocyte viability up to ~53%, which NOX and MPO inhibitors attenuate.
Why the study?
Doxorubicin-induced cardiotoxicity involves mitochondrial dysfunction and oxidative stress, but the specific mechanisms of ROS generation in cardiomyocytes remain to be elucidated.
Doxorubicin-induced cardiotoxicity in H9c2 cardiomyocytes is critically mediated by ROS generated via NADPH oxidase and myeloperoxidase, leading to mitochondrial dysfunction and apoptosis.
Answers are grounded in this paper and cite their sources.
Supports NOX/MPO inhibition in doxorubicin cardiotoxicity models; hypothesis-generating and leaves open clinical translation.
Doxorubicin (DOX), despite being an effective anti-cancer drug has offsite targets that affect the vital organs such as heart, brain and kidney.DOX-induced cardiotoxicity is reported as a multi-factorial process that interferes with mitochondrial bioenergetics.These responses increase the threshold of oxidant-mediated injury and redox-mediated apoptosis in the cardiomyocytes.Oxidative stress particularly mitochondrial dysfunction in cardiomyocytes associated with cardiovascular diseases.In the present study we examined the effect of DOX on H9c2 cardiomyocyte where cells were treated with 5 µM DOX.To rule out the source of reactive oxygen species (ROS) during DOX-induced toxicity, the DOX-treated cardiomyocytes were incubated with 100 μM diphenyleneiodonium (DPI), 50 µM salicyl hydroxamic acid (SHX), 20 µM Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), which are specific inhibitors of NADPH oxidase (NOX), Myeloperoxidase (MPO), and mitochondrial oxidative phosphorylation respectively and 10 µM N-acetyl cysteine (NAC, free radical scavenger) was also used to perceive the role of ROS.H 2 O 2 (100 μM) treated H9c2 cardiomyocytes were used as positive controls.The cell viability, reactive oxygen species (ROS) level and oxidative stress were determined using MTT assay, NBT assay/Flow-cytometry and Western blotting based assays.The effect of DOX on mitochondria was evaluated using Amplex Red assay; fluorescent probes such as MitoSOX and MitoTracker were used to examine the DOX-induced ROS production from the mitochondrial matrix.The mitochondrial membrane potential was evaluated using JC-1 dye.Western blotting was performed for cytochrome c release and apoptosis was examined with Annexin V-FITC assay.DOX was found to reduce cell viability, increase ROS level followed by enhanced oxidative stress in the form of protein carbonyls.DOX also showed a reduction in the mitochondrial membrane potential and allowed the release of cytochrome c which further leads to apoptosis and cell death.Further to rule out the pathway/mechanism(s) of DOX-mediated cardiac pathologies, the treatment with inhibitors of the classical ROS sources such as NADPH oxidase, Myeloperoxidase, mitochondria and general ROS scavenger (NAC) suggested that ROS via NOX and MPO during DOX-induced toxicity plays a crucial role in cardiomyocytes.The mitochondrial integrity was conserved when the cells were treated with NOX and MPO inhibitors, the cytochrome C release and apoptosis reduced in presence of these inhibitors.Taken together, these results demonstrate that DOX leads to ROS production and oxidative stress in cardiomyocytes which ultimately affects the mitochondrial integrity and functions, most importantly the ROS released via NOX and MPO is critical during DOX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Upadhayay et al. (2020) studied Doxorubicin-induced cardiotoxicity. Doxorubicin vs. Untreated control cells was evaluated on Cell viability and ROS generation (p=<0.05). Doxorubicin reduced cell viability by up to 53% and increased ROS levels in H9c2 cardiomyocytes, leading to mitochondrial dysfunction and apoptosis that was attenuated by NOX and MPO inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: